Core Viewpoint - Jinhe Biological reported significant growth in its half-year performance for 2025, indicating strong operational momentum and profitability improvements [2] Financial Performance - The company's operating revenue for the first half of 2025 reached approximately 1.39 billion yuan, representing a year-on-year increase of 30.45% [2] - Net profit attributable to shareholders was around 138 million yuan, marking a year-on-year increase of 51.52% [2] - Basic earnings per share were reported at 0.1787 yuan, reflecting a year-on-year increase of 53.26% [2]

Core Viewpoint - The company, Jinhe Biology, reported record-high revenue and profit for the first half of 2025, driven by strong sales in its veterinary pharmaceutical segment and a favorable cost environment [1]. Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 1.39 billion yuan, a year-on-year increase of 30.45% [1] - The net profit attributable to shareholders reached 138 million yuan, reflecting a year-on-year growth of 51.52% [1] - The overall gross margin improved by 1.25 percentage points compared to the same period last year due to a smaller increase in operating costs relative to revenue growth [1] Group 2: Veterinary Pharmaceutical Segment - The veterinary pharmaceutical segment saw continuous sales growth, particularly in the overseas market, with the main product, Chlortetracycline, experiencing increased sales both domestically and internationally [1][2] - The company has established a diversified product structure centered around Chlortetracycline premix, which is widely used in livestock industries across various regions including China, the USA, Canada, Europe, South America, Southeast Asia, India, and Vietnam [1] - The approval of Chlortetracycline premix for use in lambs by the Ministry of Agriculture and Rural Affairs in October 2024 has expanded its application scenarios [1] Group 3: Vaccine Segment - The company operates four production bases and two research centers, with 16 vaccine products currently on the market and over 20 in development or awaiting approval [2] - The company's differentiated products, such as the blue ear disease inactivated vaccine, have achieved a leading market share domestically, with over 90% of the top 50 pig farming enterprises using its solutions [2] - The overseas vaccine platform, Famawell, is gradually entering the Chinese market, with increasing customer recognition [2] Group 4: Pet Health Business - The company is actively advancing its pet health business, focusing on pharmaceutical and vaccine products, with 15 products currently available and over ten more in the application process [3] - The pet health segment is positioned as a strategic priority for the company, with expectations for rapid growth in the veterinary vaccine sector, which is anticipated to become a significant driver of future revenue [3]

Core Viewpoint - Jinhe Biology announced the convening of its 28th meeting of the 6th Board of Directors on July 30, 2025, to review the full and summary reports of the 2025 semi-annual report [2] Revenue Composition - For the year 2024, the revenue composition of Jinhe Biology is as follows: - Veterinary chemical drugs account for 52.06% - Agricultural product processing accounts for 24.53% - Veterinary biological products account for 14.5% - Environmental protection business accounts for 6.04% - Others account for 2.54% [2]

格隆汇7月30日丨金河生物(002688.SZ)公布2025年半年度报告，上半年公司实现营业收入13.90亿元，同 比增长30.45%；归属于上市公司股东的净利润1.38亿元，同比增长51.52%；归属于上市公司股东的扣除 非经常性损益的净利润1.28亿元，同比增长50.88%；基本每股收益0.1787元。 ...

金河生物科技股份有限公司 第六届董事会第二十八次会议决议公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）第六届董事会第二十八次 会议于 2025 年 7 月 20 日以电子邮件方式发出通知，并于 2025 年 7 月 30 日以通 讯方式召开，会议由董事长王东晓先生主持，应到董事 9 人，实到董事 9 人，本 次董事会出席会议董事人数符合法律法规，会议合法有效。会议召开符合《中华 人民共和国公司法》等法律、法规和《公司章程》的规定。与会董事以通讯表决 的方式审议通过了以下议案： 一、以 9 票同意，0 票反对，0 票弃权审议通过了《关于金河生物科技股份 有限公司 2025 年半年度报告全文及摘要的议案》。 证券代码：002688 证券简称：金河生物 公告编号：2025-069 1 具体内容详见公司同日于《证券时报》《中国证券报》《证券日报》《上海 证券报》及巨潮资讯网（http://www.cninfo.com.cn）披露的《关于募集资金 2025 年半年度存放、管理与使用情况的公告》（公告编号：2 ...

智通财经APP讯，金河生物(002688.SZ)发布2025年半年度报告，该公司营业收入为13.9亿元，同比增长 30.45%。归属于上市公司股东的净利润为1.38亿元，同比增长51.52%。归属于上市公司股东的扣除非经 常性损益的净利润为1.28亿元，同比增长50.88%。基本每股收益为0.1787元。 ...

Core Insights - The company Jinhe Biology (002688) reported a significant increase in revenue and net profit for the first half of 2025, with revenue reaching 1.39 billion yuan, a year-on-year growth of 30.45%, and a net profit of 138 million yuan, up 51.52% [1][1][1] - The favorable trend in the downstream pig farming industry continues to drive demand for upstream animal health products, although competition in the animal health industry remains intense [1][1][1] - The company has strategically focused on product structure and competitive advantages, emphasizing continuous research and innovation, as well as lean management internally and market orientation externally, leading to substantial growth in operating performance [1][1][1]

金河生物科技股份有限公司 2025 年半年度报告全文 2025 年半年度报告 2025 年 7 月 1 金河生物科技股份有限公司 2025 年半年度报告全文 2025 年半年度报告 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人王东晓、主管会计工作负责人牛有山及会计机构负责人(会计 主管人员)周立航声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及的经营计划及目标，属于规划性事项，不构成公司对投资 者的实质承诺。投资者应对此保持足够的风险意识，应理解经营计划与业绩 承诺之间的差异。敬请广大投资者关注，并注意投资风险。 公司在本报告第三节"管理层讨论与分析"中"十、公司面临的风险和 应对措施"部分，详细描述了公司经营中可能存在的风险，敬请投资者关注 相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 第一节 重要提示、目录和释义 2 | | --- | | 第二节 ...

金河生物（002688）公告，2025年上半年营业收入13.9亿元，同比增长30.45%。净利润1.38亿元，同比 增长51.52%。公司计划不派发现金红利，不送红股，不以公积金转增股本。 ...

2025年半年度非经营性资金占用及其他关联资金往来情况汇总表 上市公司名称：金河生物科技股份有限公司 单位：万元 企业负责人：王东晓 主管会计工作的负责人：牛有山 会计机构负责人：周立航 2,119.16万元，期末余额为-2,754.32万元，即应付金河建安2,754.32万元。 注2：上表"其他关联方资金往来-其他关联方及其附属企业"中与北京中业园净化空调工程有限公司（以下简称"北京中业园"）之间的经营性往来，期初预付款项余额为-1,448.77万元，本期向北京中业园支付173.80万元，接受劳务235.93万元，期末余额为- 1,510.90万元，即应付北京中业园1,510.90万元。 | | | 占用方与上市公司的关联关 | 上市公司核算 | 2025年期初占用 | 2025年1-6月占用累计 | 2025年1-6月占 | 2025年1-6月偿还 | 2025年1-6月期末 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 系 | 的会计科目 | 资金余额 | ...